When Mark Zuckerberg and Priscilla Chan proposed curing all disease, top scientists didn't cite scientific limits. Instead, they pointed to operational failures: data silos, unpublished information, and non-scalable tools. This revealed the core problem was engineering and infrastructure, not just pure science.

The combination of AI reasoning and robotic labs could create a new model for biotech entrepreneurship. It enables individual scientists with strong ideas to test hypotheses and generate data without raising millions for a physical lab and staff, much like cloud computing lowered the barrier for software startups.

Open-source initiatives like OpenClaw can surpass well-funded corporate R&D because they leverage a global pool of contributors. This distributed approach uncovers genius in unlikely places, allowing for breakthroughs that siloed internal teams might miss.

The key to treating rare diseases is not just CRISPR technology but a regulatory shift toward an "umbrella" or "platform" strategy. This allows multiple drugs for different mutations to be tested under a single trial, drastically lowering costs and making it feasible to develop treatments for tiny patient populations.

Mark Zuckerberg states that Biohub's goal is not to cure diseases itself, but to build open-source tools that accelerate the entire scientific field. A nonprofit model is strategically superior for this mission, as it prioritizes getting tools into more scientists' hands quickly, creating a larger collective impact than a for-profit venture could.

Fears that universal tools reduce differentiation are misplaced. Instead of just leveling the playing field, open tools like OpenFold raise the entire industry's baseline capability. This shifts competition away from who builds the best foundational model to who can ask the most insightful scientific questions.

The ultimate vision is to move beyond generalized treatments to truly individualized medicine. This involves understanding the complete causal chain from a person's unique genetic variants to the resulting protein behavior and disease. With this mechanistic understanding, it becomes possible to design a bespoke drug for that specific individual.

The Innovative Genomics Institute is tackling rare diseases by creating a standardized platform. By keeping elements like the delivery vehicle and enzyme constant and only changing the guide RNA, they aim to create a repeatable 'bucket trial' process for developing hundreds of cures, not just one-offs.

Exonic is building a platform for bioengineers to compete on open-source biological modeling, aiming to turn drug discovery into a meritocratic competition. This mirrors the model of crowdsourced hedge fund Numerai, applying a "wisdom of the crowd" approach to disrupt the closed, expensive R&D processes of large pharmaceutical companies.